The effect of 3-(5-nitro-2-thienyl)-9-chloro-5-morpholin-4-yl[1,2,4]triazolo[4,3-c]quinazoline on cell growth, cell cycle, induction of DNA fragmentation, and activity of caspase 3 in murine leukemia L1210 cells and fibroblast NIH-3T3 cells

Quinazolines are multitarget agents, which have broad spectrum of biological activity, and some of them are now in cancer clinical testing. 3‐(5‐nitro‐2‐thienyl)‐9‐chloro‐5‐morpholin‐4‐yl[1,2,4]triazolo[4,3‐c]quinazoline is a new synthetically prepared derivative, which in our previous study showed...

Full description

Saved in:
Bibliographic Details
Published inCell biochemistry and function Vol. 24; no. 6; pp. 519 - 530
Main Authors Jantova, S, Letasiova, S, Repicky, A, Ovadekova, R, Lakatos, B
Format Journal Article
LanguageEnglish
Published Chichester, UK John Wiley & Sons, Ltd 01.11.2006
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Quinazolines are multitarget agents, which have broad spectrum of biological activity, and some of them are now in cancer clinical testing. 3‐(5‐nitro‐2‐thienyl)‐9‐chloro‐5‐morpholin‐4‐yl[1,2,4]triazolo[4,3‐c]quinazoline is a new synthetically prepared derivative, which in our previous study showed cytotoxic effects on cancer cell lines HeLa and B16. Quinazoline, at micromolar concentrations, induced morphological changes and necrosis of B16 cells, and at nanomolar concentrations it produced changes of F‐actin cytoskeleton. It did not cause changes in the cell cycle, did not induce apoptotic cell death in B16 cells, did not have a mutagenic effect, and did not even behave as a typical intercalating agent. Little significant reduction of tumor volume in intramuscular transplanted B16 cells was observed. The aim of the present study was to examine the cytotoxic effect of 3‐(5‐nitro‐2‐thienyl)‐9‐chloro‐5‐morpholin‐4‐yl[1,2,4]triazolo[4,3‐c]quinazoline on murine leukemia L1210 cells and fibroblast NIH‐3T3 cells. Induction of cell morphology and cell cycle changes, induction of apoptosis and caspase 3 activity were studied. Quinazoline acted cytotoxically on both cell lines. The sensitivity of leukemia L1210 cells to the quinazoline was higher than that of fibroblast NIH‐3T3. The IC100 was 12 µM for L1210 cells and 24 µM for NIH‐3T3 cells. No effect of quinazoline on the cell cycle profile of L1210 and NIH‐3T3 was detected, however, quinazoline induced an increase of the sub‐G0 cell fraction, apoptotic DNA fragmentation, and apoptotic morphological changes at a concentration of 12 µM. This quinazoline concentration induced caspase 3 activity. Our results demonstrated that induction of apoptotic cell death via activation of caspase 3 contributed to the cytotoxic effects of 3‐(5‐nitro‐2‐thienyl)‐9‐chloro‐5‐morpholin‐4‐yl[1,2,4]triazolo[4,3‐c]quinazoline in murine leukemia L1210 cells. Copyright © 2005 John Wiley & Sons, Ltd.
AbstractList Quinazolines are multitarget agents, which have broad spectrum of biological activity, and some of them are now in cancer clinical testing. 3-(5-nitro-2- thienyl)-9-chloro-5-morpholin-4-yl[1,2,4]triazolo[4,3-c]quinazolin e is a new synthetically prepared derivative, which in our previous study showed cytotoxic effects on cancer cell lines HeLa and B16. Quinazoline, at micromolar concentrations, induced morphological changes and necrosis of B16 cells, and at nanomolar concentrations it produced changes of F-actin cytoskeleton. It did not cause changes in the cell cycle, did not induce apoptotic cell death in B16 cells, did not have a mutagenic effect, and did not even behave as a typical intercalating agent. Little significant reduction of tumor volume in intramuscular transplanted B16 cells was observed. The aim of the present study was to examine the cytotoxic effect of 3-(5-nitro-2-thienyl)-9-chloro-5- morpholin-4-yl[1,2,4]triazolo[4,3-c]quinazoline on murine leukemia L1210 cells and fibroblast NIH-3T3 cells. Induction of cell morphology and cell cycle changes, induction of apoptosis and caspase 3 activity were studied. Quinazoline acted cytotoxically on both cell lines. The sensitivity of leukemia L1210 cells to the quinazoline was higher than that of fibroblast NIH-3T3. The IC sub(100) was 12 mu M for L1210 cells and 24 mu M for NIH-3T3 cells. No effect of quinazoline on the cell cycle profile of L1210 and NIH-3T3 was detected, however, quinazoline induced an increase of the sub-G sub(0) cell fraction, apoptotic DNA fragmentation, and apoptotic morphological changes at a concentration of 12 mu M. This quinazoline concentration induced caspase 3 activity. Our results demonstrated that induction of apoptotic cell death via activation of caspase 3 contributed to the cytotoxic effects of 3-(5-nitro-2-thienyl)-9-chloro-5- morpholin-4-yl[1,2,4]triazolo[4,3-c]quinazoline in murine leukemia L1210 cells.
Abstract Quinazolines are multitarget agents, which have broad spectrum of biological activity, and some of them are now in cancer clinical testing. 3‐(5‐nitro‐2‐thienyl)‐9‐chloro‐5‐morpholin‐4‐yl[1,2,4]triazolo[4,3‐c]quinazoline is a new synthetically prepared derivative, which in our previous study showed cytotoxic effects on cancer cell lines HeLa and B16. Quinazoline, at micromolar concentrations, induced morphological changes and necrosis of B16 cells, and at nanomolar concentrations it produced changes of F‐actin cytoskeleton. It did not cause changes in the cell cycle, did not induce apoptotic cell death in B16 cells, did not have a mutagenic effect, and did not even behave as a typical intercalating agent. Little significant reduction of tumor volume in intramuscular transplanted B16 cells was observed. The aim of the present study was to examine the cytotoxic effect of 3‐(5‐nitro‐2‐thienyl)‐9‐chloro‐5‐morpholin‐4‐yl[1,2,4]triazolo[4,3‐c]quinazoline on murine leukemia L1210 cells and fibroblast NIH‐3T3 cells. Induction of cell morphology and cell cycle changes, induction of apoptosis and caspase 3 activity were studied. Quinazoline acted cytotoxically on both cell lines. The sensitivity of leukemia L1210 cells to the quinazoline was higher than that of fibroblast NIH‐3T3. The IC 100 was 12 µM for L1210 cells and 24 µM for NIH‐3T3 cells. No effect of quinazoline on the cell cycle profile of L1210 and NIH‐3T3 was detected, however, quinazoline induced an increase of the sub‐G 0 cell fraction, apoptotic DNA fragmentation, and apoptotic morphological changes at a concentration of 12 µM. This quinazoline concentration induced caspase 3 activity. Our results demonstrated that induction of apoptotic cell death via activation of caspase 3 contributed to the cytotoxic effects of 3‐(5‐nitro‐2‐thienyl)‐9‐chloro‐5‐morpholin‐4‐yl[1,2,4]triazolo[4,3‐c]quinazoline in murine leukemia L1210 cells. Copyright © 2005 John Wiley & Sons, Ltd.
Quinazolines are multitarget agents, which have broad spectrum of biological activity, and some of them are now in cancer clinical testing. 3-(5-nitro-2-thienyl)-9-chloro-5-morpholin-4-yl[1,2,4]triazolo[4,3-c]quinazoline is a new synthetically prepared derivative, which in our previous study showed cytotoxic effects on cancer cell lines HeLa and B16. Quinazoline, at micromolar concentrations, induced morphological changes and necrosis of B16 cells, and at nanomolar concentrations it produced changes of F-actin cytoskeleton. It did not cause changes in the cell cycle, did not induce apoptotic cell death in B16 cells, did not have a mutagenic effect, and did not even behave as a typical intercalating agent. Little significant reduction of tumor volume in intramuscular transplanted B16 cells was observed. The aim of the present study was to examine the cytotoxic effect of 3-(5-nitro-2-thienyl)-9-chloro-5-morpholin-4-yl[1,2,4]triazolo[4,3-c]quinazoline on murine leukemia L1210 cells and fibroblast NIH-3T3 cells. Induction of cell morphology and cell cycle changes, induction of apoptosis and caspase 3 activity were studied. Quinazoline acted cytotoxically on both cell lines. The sensitivity of leukemia L1210 cells to the quinazoline was higher than that of fibroblast NIH-3T3. The IC(100) was 12 microM for L1210 cells and 24 microM for NIH-3T3 cells. No effect of quinazoline on the cell cycle profile of L1210 and NIH-3T3 was detected, however, quinazoline induced an increase of the sub-G(0) cell fraction, apoptotic DNA fragmentation, and apoptotic morphological changes at a concentration of 12 microM. This quinazoline concentration induced caspase 3 activity. Our results demonstrated that induction of apoptotic cell death via activation of caspase 3 contributed to the cytotoxic effects of 3-(5-nitro-2-thienyl)-9-chloro-5-morpholin-4-yl[1,2,4]triazolo[4,3-c]quinazoline in murine leukemia L1210 cells.
Quinazolines are multitarget agents, which have broad spectrum of biological activity, and some of them are now in cancer clinical testing. 3‐(5‐nitro‐2‐thienyl)‐9‐chloro‐5‐morpholin‐4‐yl[1,2,4]triazolo[4,3‐c]quinazoline is a new synthetically prepared derivative, which in our previous study showed cytotoxic effects on cancer cell lines HeLa and B16. Quinazoline, at micromolar concentrations, induced morphological changes and necrosis of B16 cells, and at nanomolar concentrations it produced changes of F‐actin cytoskeleton. It did not cause changes in the cell cycle, did not induce apoptotic cell death in B16 cells, did not have a mutagenic effect, and did not even behave as a typical intercalating agent. Little significant reduction of tumor volume in intramuscular transplanted B16 cells was observed. The aim of the present study was to examine the cytotoxic effect of 3‐(5‐nitro‐2‐thienyl)‐9‐chloro‐5‐morpholin‐4‐yl[1,2,4]triazolo[4,3‐c]quinazoline on murine leukemia L1210 cells and fibroblast NIH‐3T3 cells. Induction of cell morphology and cell cycle changes, induction of apoptosis and caspase 3 activity were studied. Quinazoline acted cytotoxically on both cell lines. The sensitivity of leukemia L1210 cells to the quinazoline was higher than that of fibroblast NIH‐3T3. The IC100 was 12 µM for L1210 cells and 24 µM for NIH‐3T3 cells. No effect of quinazoline on the cell cycle profile of L1210 and NIH‐3T3 was detected, however, quinazoline induced an increase of the sub‐G0 cell fraction, apoptotic DNA fragmentation, and apoptotic morphological changes at a concentration of 12 µM. This quinazoline concentration induced caspase 3 activity. Our results demonstrated that induction of apoptotic cell death via activation of caspase 3 contributed to the cytotoxic effects of 3‐(5‐nitro‐2‐thienyl)‐9‐chloro‐5‐morpholin‐4‐yl[1,2,4]triazolo[4,3‐c]quinazoline in murine leukemia L1210 cells. Copyright © 2005 John Wiley & Sons, Ltd.
Author Repický, A.
Jantová, S.
Letašiová, S.
Ovádeková, R.
Lakatoš, B.
Author_xml – sequence: 1
  givenname: S
  surname: Jantova
  fullname: Jantova, S
– sequence: 2
  givenname: S
  surname: Letasiova
  fullname: Letasiova, S
– sequence: 3
  givenname: A
  surname: Repicky
  fullname: Repicky, A
– sequence: 4
  givenname: R
  surname: Ovadekova
  fullname: Ovadekova, R
– sequence: 5
  givenname: B
  surname: Lakatos
  fullname: Lakatos, B
BackLink https://www.ncbi.nlm.nih.gov/pubmed/16342136$$D View this record in MEDLINE/PubMed
BookMark eNp1kV1v0zAUhiM0xLqBxC9AvkJDioe_4iaXW2HdpFIkVD6kabIc117NHLuzE0b41fwEkrWCK66Oz_FzHlt6j7IDH7zOspcYnWKEyFtVm1NMKv4km2BUVRCVjB1kE0Q4hZyV7DA7Suk7QqjiFD3LDjGnjGDKJ9nv1UYDbYxWLQgGUHhSQG_bGCCB7cZq37s3sIJq48IwK2AT4nYTnPWQwd5d45zk7KaNVv4KLlyznEJ1c99ZP_bWaxA8UNo5cBvDQ7vJd43qldM5sH7dqdYOyPDyu-UZMFHeNtq3chzmQPo1kAPww7b9iCiZtjJpQIdN0HRx9Dvd3enGSrDABKNHfXpcNLaOoXYytWB5dQnpiu4un2dPjXRJv9jX4-zzxfvV7BIuPs6vZmcLqGhZcliboiq0Kk01lDUjaDhjNsWKIlYhjTFZ11OmCTecFJxJJQnVBtfcVKYuUEWPs9c77zaG-06nVjQ2jT-QXocuCYIwKSkpBvBkB6oYUoraiG20jYy9wEiM6YohXTGmO6Cv9s6ubvT6H7iPcwDgDniwTvf_FYnZ-cVeuOdtavXPv7yMd4JP6bQQX5dzMcdk-en8wzfxhf4BcPC-qQ
CitedBy_id crossref_primary_10_1016_j_jphotobiol_2010_09_007
crossref_primary_10_1016_j_jphotobiol_2015_11_014
crossref_primary_10_1016_j_molstruc_2024_137822
crossref_primary_10_1002_cbf_1421
crossref_primary_10_1021_jo900428j
crossref_primary_10_3987_COM_10_12093
crossref_primary_10_1039_c3ra46796a
crossref_primary_10_1007_s00216_009_2740_x
crossref_primary_10_1007_s00604_008_0068_4
crossref_primary_10_1021_jo5013288
crossref_primary_10_1039_D2MD00023G
crossref_primary_10_1021_jm400394s
crossref_primary_10_4155_fmc_2017_0284
Cites_doi 10.1097/00001813-199701000-00001
10.1016/S0016-5085(98)70312-9
10.2337/diabetes.48.3.609
10.1016/j.bcp.2004.06.006
10.1016/S0021-9258(19)52451-6
10.1023/B:APPT.0000012124.30095.09
10.1016/0006-2952(95)02156-6
10.1038/sj.bjc.6601873
10.1007/978-1-4615-0081-0_19
10.1046/j.1440-1827.2001.01204.x
10.1016/S1368-8375(03)00131-3
10.1002/jhet.5570290117
10.1135/cccc19911719
10.1097/00001813-200409000-00011
10.1007/BF02931453
10.1007/BF00689203
10.1002/ardp.19903231004
10.1021/jm00089a021
10.1007/s002800050608
10.1016/S1368-8375(98)00118-3
10.1158/0008-5472.CAN-04-1905
10.1097/01.ju.0000138524.18870.af
10.1093/jnci/82.9.749
10.1110/ps.8.3.467
10.1021/bi981881d
10.1038/sj.bjc.6602108
10.1016/S0014-827X(98)00002-0
10.1038/bjc.1998.747
10.1124/jpet.102.039651
ContentType Journal Article
Copyright Copyright © 2005 John Wiley & Sons, Ltd.
Copyright (c) 2005 John Wiley & Sons, Ltd.
Copyright_xml – notice: Copyright © 2005 John Wiley & Sons, Ltd.
– notice: Copyright (c) 2005 John Wiley & Sons, Ltd.
DBID BSCLL
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7TM
DOI 10.1002/cbf.1296
DatabaseName Istex
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Nucleic Acids Abstracts
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Nucleic Acids Abstracts
DatabaseTitleList Nucleic Acids Abstracts
CrossRef
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
Biology
EISSN 1099-0844
EndPage 530
ExternalDocumentID 10_1002_cbf_1296
16342136
CBF1296
ark_67375_WNG_G12NRBMX_V
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Ministry of Education of the Slovak Republic
  funderid: APVT‐20‐007304
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
29B
31~
33P
3SF
3WU
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5VS
66C
6J9
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BLYAC
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR1
DR2
DRFUL
DRMAN
DRSTM
DU5
EBD
EBS
EJD
EMOBN
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GNP
GODZA
H.X
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KBYEO
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LH6
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NDZJH
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
Q.N
Q11
QB0
QRW
R.K
RBB
RIWAO
RJQFR
ROL
RWI
RX1
RYL
SAMSI
SUPJJ
SV3
TEORI
UB1
V2E
V8K
W8V
W99
WBKPD
WH7
WIB
WIH
WIJ
WIK
WJL
WNSPC
WOHZO
WQJ
WRC
WSB
WXI
WXSBR
WYISQ
XG1
XPP
XV2
ZZTAW
~IA
~WT
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7TM
ID FETCH-LOGICAL-c3886-bf595ec8f995ed420ec81471c30490e112db74e26f62564aca23ef1b6f9fb5093
IEDL.DBID DR2
ISSN 0263-6484
IngestDate Fri Aug 16 07:20:49 EDT 2024
Fri Aug 23 01:49:18 EDT 2024
Sat Sep 28 07:48:47 EDT 2024
Sat Aug 24 00:55:55 EDT 2024
Wed Oct 30 09:48:09 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
License Copyright (c) 2005 John Wiley & Sons, Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3886-bf595ec8f995ed420ec81471c30490e112db74e26f62564aca23ef1b6f9fb5093
Notes Ministry of Education of the Slovak Republic - No. APVT-20-007304
istex:731B420174A111D0213CECE013A0259759658A0B
ArticleID:CBF1296
ark:/67375/WNG-G12NRBMX-V
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 16342136
PQID 20128325
PQPubID 23462
PageCount 12
ParticipantIDs proquest_miscellaneous_20128325
crossref_primary_10_1002_cbf_1296
pubmed_primary_16342136
wiley_primary_10_1002_cbf_1296_CBF1296
istex_primary_ark_67375_WNG_G12NRBMX_V
PublicationCentury 2000
PublicationDate November/December 2006
PublicationDateYYYYMMDD 2006-11-01
PublicationDate_xml – month: 11
  year: 2006
  text: November/December 2006
PublicationDecade 2000
PublicationPlace Chichester, UK
PublicationPlace_xml – name: Chichester, UK
– name: England
PublicationTitle Cell biochemistry and function
PublicationTitleAlternate Cell Biochem. Funct
PublicationYear 2006
Publisher John Wiley & Sons, Ltd
Publisher_xml – name: John Wiley & Sons, Ltd
References Kaye SB. New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer 1998; 78: 1-7.
Austin PF, Cook BL, Niederhoff RA, Manson SR, Coplen DE, Weintraub SJ. Inhibition of mitogenic signaling and induction of apoptosis in human bladder smooth muscle cells treated with doxazosin. J Urol 2004; 4: 1662-1665.
Špirková K, Stankovský Š, Horňáček J. Amidinoyl isothiocyanates in the synthesis of condensed quinazolines. Preparation of 3-aryl-5,9-disubstituted s-triazolo[4,3-c] quinazolines and their [1,5-c]isomers. Chem Paper 1993; 6: 382-385.
Kornet MJ. Synthesis and anticonvulsant activity of 3-alkyl-3,4-dihydro-2(1H)-quinazolinones. J Heterocyclic Chem 1992; 29: 103-105.
Loriga M, Vitale G, Paglietti G. Quinoxaline chemistry. Part 9. Quinoxaline analogues of trimetrexate (TMQ) and 10-propargyl-5,8-dideazafolic acid (CB3717) and its precursors. Synthesis and evaluation of in vitro anticancer activity. Farmaco 1998; 53: 139-149.
Pomarnacka E, Angielski S, Hoppe A. Derivatives of 4-chloro-5-sulfanoyl-benzoic acid. 8. Synthesis and diuretic activity of pyrazole[3,2-b] quinazoline and 1-benzoylpyrazole derivatives. Acta Polon Pharm 1984; 41: 141-151.
Polshakov VI, Birdsall B, Frenkiel TA, Gargaro AR, Feeney J. Structure and dynamics in solution of the complex of Lactobacillus casei dihydrofolate reductase with the new lipophilic antifolate drug trimetrexate. Protein Sci 1999; 8: 467-481.
Takemura Y, Jackman A. Folate-based thymidylate synthase inhibitors in cancer chemotherapy. Anti-Cancer Drugs 1997; 8: 3-16.
Tonkinson JL, Marder P, Andis SL, et al. Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostatis. Cancer Chemother Pharmacol 1997; 39: 521-531.
Fumarola C, Guidotii GG. Stress-induced apoptosi: toward a symmetry with receptor-mediated cell death. Apoptosis 2004; 9: 77-82.
Kimoto T, Hino K, Koya-Miyata S, et al. Cell differentiation and apoptosis of monocytic and promyelocytic leukemia cells (U-937 and HL-60) by tryptanthrin, an active ingredient of Polygonum tinctorium Lour. Pathol Int 2001; 5: 315-325.
Grunwald V, Hidalgo M. Development of the epidermal growth factor receptor inhibitor tarceva (OSI-774). Edv Exp Med Biol 2003; 532: 235-246.
Shimoyama M, Ogino K, Tanaka Y, Ikeda T, Hisatome I. Hemodynamic basic for the acute cardiac effects of troglitazone in isolated perfused rat hearts. Diabetes 1999; 3: 609-615.
Naithani PK, Palit G, Srivastava VK, Shanker K. 2,3-Disubstituted quinazolinones and their antiparkinsonian activity. Ind J Chem Sect B, Org Chem Incl Med Chem 1989; 28: 745-750.
Karnes WE, Weller SG, Adjei PN, et al. Inhibition of epidermal growth factor receptor kinase induces protease-dependent apotosis in human colon cancer cells. Gastroenterology 1998; 5: 930-939.
Abdel-Rahman TM. Synthesis of some new biologically active 2,3-disubstituted quinazolin-4-ones. Boll Chim Farm 1998; 137: 43-47.
Faust RA, Tawfic S, Davis AT, Ahmed K. Apoptosis and growth inhibition of head and neck tumor cell line induced by epidermal growth factor receptor tyrosine kinase inhibitor. Oral Oncol 1999; 35: 290-295.
Bos M, Mendelsohn J, Kim YM, Albanell J, Fry DW, Baselga J. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res 1997; 3: 2099-2106.
Sorenson CHM, Barry MA, Eastman A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 1990; 82: 749-754.
Chang GCH, Hsu SL, Tsai JR, et al. Molecular mechanism of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells. Biochem Pharm 2004; 68: 1453-1464.
Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6: 2053-2063.
Sandstrom M, Johansson M, Andersson U, Bergh A, Bergenheim A, Henriksson R. The tyrosine kinase inhibitor ZD6474 inhibitors tumour growth in an intracerebral rat glioma model. Br J Cancer 2004; 6: 1174-1180.
Scott CW, Sobotka-Briner C, Wilkins DE, et al. Novel small molecule inhibitors of caspase 3 block cellular and biochemical features of apoptosis. J Pharmacol Exp Ther 2003; 1: 433-440.
Shintani S, Li C, Mihara M, et al. Gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up-regulates p27KIP1 and induces G1 arrest in oral squamous cell carcinoma cell lines. Oral Onco 2004; 1: 43-51.
Jantovnnná S, Urbančíková M,Maliar T, et al. Biological activity of some 4-anilinoquinazolines: cytotoxic, genotoxic and antiprotease effects, induction of necrosis and changes of actin cytoskeleton. Neoplasma 2001; 1: 52-60.
Špirková K, Stankovský Š. Amidinoyl isothiocyanates in the synthesis of condensed quinazolines. Preparation of 3-aryl-5,9-disubstituted s-triazolo[4,3-c]quinazolines. Collect Czech Chem Commun 1991; 56: 1719-1724.
Park JK, Lee SH, Kang JH, Nishio K, Saijo N, Kuh HJ. Synergistic interaction between gefitinib (Iressa, ZD1839) and oarlitaxel against human gastric carcinoma cells. Anticancer Drugs 2004; 8: 809-818.
Chang GC, Hsu SL, Tsai JR, et al. Molecular mechanism of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells. Biochem Pharmacol 2004; 7: 1453-1464.
Ranson M. Epidermal growth factor receptor tyrosine kinase inhibitors. Br J Cancer 2004; 90: 2250-2255.
Narla RK, Liu XP, Myers DE, Uckun FM. 4-(3α-Bromo-4'hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells. Clin Cancer Res 1998; 4: 1405-1414.
Karnes Jr WE, Weller SG, Adjei PN, et al. Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cell. Gastroenterology 1998; 114: 930-939.
Farghaly AM, Chaaban I, Khalil MA, Bekhit AA. Non-steroidal antiinflammatory agents. Synthesis of novel 2-pyrazolyl-4(3)-quinazolinones. Arch Pharmacol 1990; 323: 833-836.
Kimoto T, Hino K, Koya-Miyata S, et al. Cell differentiation and apoptosis of monocytic and promyeloytic leukemia cells (U-937 and HL-60) by tryptanthin, an active ingredient of Polygonum tinctorium Lour. Pathol Int 2001; 51: 315-325.
Sotelo-Mundo RR, Ciesla J, Dzík JM, et al. Crystal structures of rat thymidylate synthase inhibited by Tomudex, a potent anticancer drug. Biochemistry 1990; 38: 1087-1094.
Jantová S, Ovádeková R, Letašiová S, Špirková K, Stankovský Š. Antimicrobial activity of some substituted triazoloquinazolines. Folia Microbiol 2005; 2: 90-94.
Yamagishi M, Yamada Y, Ozaki K, et al. Biological activities and quantitative structure-activity relationships of spiro[imidazolidine-4-4'-(1H) quinazoline]-2,2,5(H)-triones as aldose reductase inhibitors. J Med Chem 1992; 35: 2085-2094.
Yang JS, Hour MJ, Kuo SC, Huang LJ, Lee MR. Selective induction of G2/M arrest and apoptosis in HL-60 by a potent anticancer agent, HMJ-38. Anticancer Res 2004; 24: 1769-1778.
Modjtahedi H, Affleck K, Stubberfield C, Dean C. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5. Int J Oncol 1998: 13: 335-342.
Yang JS, Hour MJ, Kuo SC, Huang LJ, Lee MR. Selective induction of G2/M arrest and apoptosis in HL-60 by a potent anticancer agent, HMJ-38. Anticancer Res 2004; 3a: 1769-1778.
Chiang CF, Son EL, Wu GJ. Oral treatment of the TRAMP mice with doxazosin suppresses prostate tumor growth and metastasis. Prostate 2005; 4: 1778-1783.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 143: 265.
Janmaat ML, Kruyt FAE, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003; 9: 2316-2326.
Holden SA, Teicher BA, Robinson MF, Northey D. Rosowsky A. Antifolates can potentiate topoisomerase II inhibitors in vitro and in vivo. Cancer Chemother 1995; 36: 165-171.
Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, Janne PA. Gefitinib induces apoptosis in the EGFR L858R non-small-cell lung cancer cell line H3255. Cancer Res 2004; 20: 7241-7244.
Hamel E, Lin CM, Plowman J, Wang H, Lee KH, Paull KD. Antitumour 2,3-dihydro-2-(aryl)-4(1H)-quinazolinone derivatives. Interactions with tubulin. Biochem Pharmacol 1996; 51: 53-59.
1984; 41
2004; 20
1990; 323
1991; 56
2000; 6
1990; 38
1995; 36
2004; 8
2004; 7
2004; 68
2004; 9
2004; 24
2004; 4
2004; 6
1996; 51
2004; 3a
1998; 137
1992; 35
2005
1999; 3
1951; 143
1998; 114
2004; 1
2004; 90
1999; 8
2003; 532
1997; 3
1990; 82
1989; 28
1997; 8
1993; 6
1963; 1
2001; 5
2003; 9
1999; 35
1992; 29
2005; 4
1997; 39
2001; 1
2005; 2
2003; 1
1998; 5
1998; 53
1998; 4
1998; 78
2001; 51
1998; 13
Bos M (e_1_2_1_16_2) 1997; 3
Narla RK (e_1_2_1_30_2) 1998; 4
Modjtahedi H (e_1_2_1_20_2) 1998; 13
Lowry OH (e_1_2_1_27_2) 1951; 143
Špirková K (e_1_2_1_24_2) 1993; 6
Letašiová S (e_1_2_1_26_2) 2005
e_1_2_1_40_2
e_1_2_1_22_2
e_1_2_1_23_2
e_1_2_1_44_2
Wiseloge FW (e_1_2_1_2_2) 1963
e_1_2_1_43_2
e_1_2_1_21_2
e_1_2_1_42_2
Ciardiello F (e_1_2_1_32_2) 2000; 6
e_1_2_1_25_2
e_1_2_1_46_2
Naithani PK (e_1_2_1_9_2) 1989; 28
Pomarnacka E (e_1_2_1_5_2) 1984; 41
e_1_2_1_28_2
e_1_2_1_29_2
Sandstrom M (e_1_2_1_38_2) 2004; 6
Janmaat ML (e_1_2_1_45_2) 2003; 9
e_1_2_1_6_2
Jantovnnná S (e_1_2_1_12_2) 2001; 1
e_1_2_1_7_2
e_1_2_1_4_2
e_1_2_1_11_2
e_1_2_1_34_2
Yang JS (e_1_2_1_41_2) 2004; 3
e_1_2_1_33_2
e_1_2_1_10_2
e_1_2_1_31_2
e_1_2_1_15_2
Abdel‐Rahman TM (e_1_2_1_3_2) 1998; 137
e_1_2_1_37_2
e_1_2_1_13_2
e_1_2_1_36_2
Yang JS (e_1_2_1_47_2) 2004; 24
e_1_2_1_14_2
e_1_2_1_35_2
e_1_2_1_19_2
e_1_2_1_8_2
e_1_2_1_17_2
Chiang CF (e_1_2_1_48_2) 2005; 4
e_1_2_1_18_2
e_1_2_1_39_2
References_xml – volume: 29
  start-page: 103
  year: 1992
  end-page: 105
  article-title: Synthesis and anticonvulsant activity of 3‐alkyl‐3,4‐dihydro‐2(1H)‐quinazolinones
  publication-title: J Heterocyclic Chem
– volume: 51
  start-page: 315
  year: 2001
  end-page: 325
  article-title: Cell differentiation and apoptosis of monocytic and promyeloytic leukemia cells (U‐937 and HL‐60) by tryptanthin, an active ingredient of Lour
  publication-title: Pathol Int
– volume: 4
  start-page: 1662
  year: 2004
  end-page: 1665
  article-title: Inhibition of mitogenic signaling and induction of apoptosis in human bladder smooth muscle cells treated with doxazosin
  publication-title: J Urol
– volume: 9
  start-page: 77
  year: 2004
  end-page: 82
  article-title: Stress‐induced apoptosi: toward a symmetry with receptor‐mediated cell death
  publication-title: Apoptosis
– volume: 9
  start-page: 2316
  year: 2003
  end-page: 2326
  article-title: Response to epidermal growth factor receptor inhibitors in non‐small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal‐regulated kinase or Akt kinase pathways
  publication-title: Clin Cancer Res
– volume: 39
  start-page: 521
  year: 1997
  end-page: 531
  article-title: Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostatis
  publication-title: Cancer Chemother Pharmacol
– volume: 82
  start-page: 749
  year: 1990
  end-page: 754
  article-title: Analysis of events associated with cell cycle arrest at G phase and cell death induced by cisplatin
  publication-title: J Natl Cancer Inst
– volume: 532
  start-page: 235
  year: 2003
  end-page: 246
  article-title: Development of the epidermal growth factor receptor inhibitor tarceva (OSI‐774)
  publication-title: Edv Exp Med Biol
– volume: 6
  start-page: 1174
  year: 2004
  end-page: 1180
  article-title: The tyrosine kinase inhibitor ZD6474 inhibitors tumour growth in an intracerebral rat glioma model
  publication-title: Br J Cancer
– volume: 38
  start-page: 1087
  year: 1990
  end-page: 1094
  article-title: Crystal structures of rat thymidylate synthase inhibited by Tomudex, a potent anticancer drug
  publication-title: Biochemistry
– volume: 51
  start-page: 53
  year: 1996
  end-page: 59
  article-title: Antitumour 2,3‐dihydro‐2‐(aryl)‐4(1H)‐quinazolinone derivatives. Interactions with tubulin
  publication-title: Biochem Pharmacol
– volume: 1
  start-page: 43
  year: 2004
  end-page: 51
  article-title: Gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up‐regulates p27KIP1 and induces G arrest in oral squamous cell carcinoma cell lines
  publication-title: Oral Onco
– volume: 4
  start-page: 1405
  year: 1998
  end-page: 1414
  article-title: 4‐(3α‐Bromo‐4'hydroxylphenyl)‐amino‐6,7‐dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells
  publication-title: Clin Cancer Res
– volume: 1
  start-page: 433
  year: 2003
  end-page: 440
  article-title: Novel small molecule inhibitors of caspase 3 block cellular and biochemical features of apoptosis
  publication-title: J Pharmacol Exp Ther
– volume: 8
  start-page: 467
  year: 1999
  end-page: 481
  article-title: Structure and dynamics in solution of the complex of dihydrofolate reductase with the new lipophilic antifolate drug trimetrexate
  publication-title: Protein Sci
– volume: 323
  start-page: 833
  year: 1990
  end-page: 836
  article-title: Non‐steroidal antiinflammatory agents. Synthesis of novel 2‐pyrazolyl‐4(3)‐quinazolinones
  publication-title: Arch Pharmacol
– volume: 8
  start-page: 3
  year: 1997
  end-page: 16
  article-title: Folate‐based thymidylate synthase inhibitors in cancer chemotherapy
  publication-title: Anti‐Cancer Drugs
– volume: 3a
  start-page: 1769
  year: 2004
  end-page: 1778
  article-title: Selective induction of G /M arrest and apoptosis in HL‐60 by a potent anticancer agent, HMJ‐38
  publication-title: Anticancer Res
– volume: 114
  start-page: 930
  year: 1998
  end-page: 939
  article-title: Inhibition of epidermal growth factor receptor kinase induces protease‐dependent apoptosis in human colon cancer cell
  publication-title: Gastroenterology
– volume: 5
  start-page: 930
  year: 1998
  end-page: 939
  article-title: Inhibition of epidermal growth factor receptor kinase induces protease‐dependent apotosis in human colon cancer cells
  publication-title: Gastroenterology
– volume: 24
  start-page: 1769
  year: 2004
  end-page: 1778
  article-title: Selective induction of G /M arrest and apoptosis in HL‐60 by a potent anticancer agent, HMJ‐38
  publication-title: Anticancer Res
– volume: 35
  start-page: 2085
  year: 1992
  end-page: 2094
  article-title: Biological activities and quantitative structure–activity relationships of spiro[imidazolidine‐4‐4'‐(1H) quinazoline]‐2,2,5(H)‐triones as aldose reductase inhibitors
  publication-title: J Med Chem
– volume: 1
  start-page: 304
  year: 1963
– volume: 3
  start-page: 609
  year: 1999
  end-page: 615
  article-title: Hemodynamic basic for the acute cardiac effects of troglitazone in isolated perfused rat hearts
  publication-title: Diabetes
– volume: 137
  start-page: 43
  year: 1998
  end-page: 47
  article-title: Synthesis of some new biologically active 2,3‐disubstituted quinazolin‐4‐ones
  publication-title: Boll Chim Farm
– volume: 3
  start-page: 2099
  year: 1997
  end-page: 2106
  article-title: PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number‐dependent manner
  publication-title: Clin Cancer Res
– volume: 13
  start-page: 335
  year: 1998
  end-page: 342
  article-title: EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5
  publication-title: Int J Oncol
– volume: 1
  start-page: 52
  year: 2001
  end-page: 60
  article-title: Biological activity of some 4‐anilinoquinazolines: cytotoxic, genotoxic and antiprotease effects, induction of necrosis and changes of actin cytoskeleton
  publication-title: Neoplasma
– volume: 8
  start-page: 809
  year: 2004
  end-page: 818
  article-title: Synergistic interaction between gefitinib (Iressa, ZD1839) and oarlitaxel against human gastric carcinoma cells
  publication-title: Anticancer Drugs
– volume: 53
  start-page: 139
  year: 1998
  end-page: 149
  article-title: Quinoxaline chemistry. Part 9. Quinoxaline analogues of trimetrexate (TMQ) and 10‐propargyl‐5,8‐dideazafolic acid (CB3717) and its precursors. Synthesis and evaluation of anticancer activity
  publication-title: Farmaco
– volume: 6
  start-page: 382
  year: 1993
  end-page: 385
  article-title: Amidinoyl isothiocyanates in the synthesis of condensed quinazolines. Preparation of 3‐aryl‐5,9‐disubstituted ‐triazolo[4,3 ] quinazolines and their [1,5 ]isomers
  publication-title: Chem Paper
– volume: 28
  start-page: 745
  year: 1989
  end-page: 750
  article-title: 2,3‐Disubstituted quinazolinones and their antiparkinsonian activity
  publication-title: Ind J Chem Sect B, Org Chem Incl Med Chem
– volume: 78
  start-page: 1
  year: 1998
  end-page: 7
  article-title: New antimetabolites in cancer chemotherapy and their clinical impact
  publication-title: Br J Cancer
– volume: 5
  start-page: 315
  year: 2001
  end-page: 325
  article-title: Cell differentiation and apoptosis of monocytic and promyelocytic leukemia cells (U‐937 and HL‐60) by tryptanthrin, an active ingredient of Lour
  publication-title: Pathol Int
– volume: 68
  start-page: 1453
  year: 2004
  end-page: 1464
  article-title: Molecular mechanism of ZD1839‐induced G ‐cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells
  publication-title: Biochem Pharm
– volume: 35
  start-page: 290
  year: 1999
  end-page: 295
  article-title: Apoptosis and growth inhibition of head and neck tumor cell line induced by epidermal growth factor receptor tyrosine kinase inhibitor
  publication-title: Oral Oncol
– volume: 41
  start-page: 141
  year: 1984
  end-page: 151
  article-title: Derivatives of 4‐chloro‐5‐sulfanoyl‐benzoic acid. 8. Synthesis and diuretic activity of pyrazole[3,2‐ ] quinazoline and 1‐benzoylpyrazole derivatives
  publication-title: Acta Polon Pharm
– volume: 36
  start-page: 165
  year: 1995
  end-page: 171
  article-title: Antifolates can potentiate topoisomerase II inhibitors and
  publication-title: Cancer Chemother
– volume: 143
  start-page: 265
  year: 1951
  article-title: Protein measurement with the Folin phenol reagent
  publication-title: J Biol Chem
– volume: 20
  start-page: 7241
  year: 2004
  end-page: 7244
  article-title: Gefitinib induces apoptosis in the EGFR L858R non‐small‐cell lung H3255
  publication-title: Cancer Res
– volume: 2
  start-page: 90
  year: 2005
  end-page: 94
  article-title: Antimicrobial activity of some substituted triazoloquinazolines
  publication-title: Folia Microbiol
– start-page: 74
  year: 2005
– volume: 7
  start-page: 1453
  year: 2004
  end-page: 1464
  article-title: Molecular mechanism of ZD1839‐induced G ‐cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells
  publication-title: Biochem Pharmacol
– volume: 4
  start-page: 1778
  year: 2005
  end-page: 1783
  article-title: Oral treatment of the TRAMP mice with doxazosin suppresses prostate tumor growth and metastasis
  publication-title: Prostate
– volume: 90
  start-page: 2250
  year: 2004
  end-page: 2255
  article-title: Epidermal growth factor receptor tyrosine kinase inhibitors
  publication-title: Br J Cancer
– volume: 56
  start-page: 1719
  year: 1991
  end-page: 1724
  article-title: Amidinoyl isothiocyanates in the synthesis of condensed quinazolines. Preparation of 3‐aryl‐5,9‐disubstituted ‐triazolo[4,3‐ ]quinazolines
  publication-title: Collect Czech Chem Commun
– volume: 6
  start-page: 2053
  year: 2000
  end-page: 2063
  article-title: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD‐1839 (Iressa), an epidermal growth factor receptor‐selective tyrosine kinase inhibitor
  publication-title: Clin Cancer Res
– volume: 6
  start-page: 2053
  year: 2000
  ident: e_1_2_1_32_2
  article-title: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD‐1839 (Iressa), an epidermal growth factor receptor‐selective tyrosine kinase inhibitor
  publication-title: Clin Cancer Res
  contributor:
    fullname: Ciardiello F
– volume: 41
  start-page: 141
  year: 1984
  ident: e_1_2_1_5_2
  article-title: Derivatives of 4‐chloro‐5‐sulfanoyl‐benzoic acid. 8. Synthesis and diuretic activity of pyrazole[3,2‐b] quinazoline and 1‐benzoylpyrazole derivatives
  publication-title: Acta Polon Pharm
  contributor:
    fullname: Pomarnacka E
– ident: e_1_2_1_18_2
  doi: 10.1097/00001813-199701000-00001
– ident: e_1_2_1_29_2
  doi: 10.1016/S0016-5085(98)70312-9
– volume: 6
  start-page: 382
  year: 1993
  ident: e_1_2_1_24_2
  article-title: Amidinoyl isothiocyanates in the synthesis of condensed quinazolines. Preparation of 3‐aryl‐5,9‐disubstituted s‐triazolo[4,3‐c] quinazolines and their [1,5‐c]isomers
  publication-title: Chem Paper
  contributor:
    fullname: Špirková K
– ident: e_1_2_1_7_2
  doi: 10.2337/diabetes.48.3.609
– ident: e_1_2_1_37_2
  doi: 10.1016/j.bcp.2004.06.006
– start-page: 74
  volume-title: Abstract of XXIII. Xenobiochemic Symposium in Valtice
  year: 2005
  ident: e_1_2_1_26_2
  contributor:
    fullname: Letašiová S
– volume: 143
  start-page: 265
  year: 1951
  ident: e_1_2_1_27_2
  article-title: Protein measurement with the Folin phenol reagent
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(19)52451-6
  contributor:
    fullname: Lowry OH
– ident: e_1_2_1_42_2
  doi: 10.1023/B:APPT.0000012124.30095.09
– ident: e_1_2_1_19_2
  doi: 10.1016/0006-2952(95)02156-6
– ident: e_1_2_1_14_2
  doi: 10.1038/sj.bjc.6601873
– ident: e_1_2_1_39_2
  doi: 10.1007/978-1-4615-0081-0_19
– ident: e_1_2_1_33_2
  doi: 10.1046/j.1440-1827.2001.01204.x
– ident: e_1_2_1_34_2
  doi: 10.1016/S1368-8375(03)00131-3
– volume: 3
  start-page: 2099
  year: 1997
  ident: e_1_2_1_16_2
  article-title: PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number‐dependent manner
  publication-title: Clin Cancer Res
  contributor:
    fullname: Bos M
– ident: e_1_2_1_28_2
  doi: 10.1016/j.bcp.2004.06.006
– ident: e_1_2_1_6_2
  doi: 10.1002/jhet.5570290117
– ident: e_1_2_1_23_2
  doi: 10.1135/cccc19911719
– volume: 4
  start-page: 1405
  year: 1998
  ident: e_1_2_1_30_2
  article-title: 4‐(3α‐Bromo‐4'hydroxylphenyl)‐amino‐6,7‐dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells
  publication-title: Clin Cancer Res
  contributor:
    fullname: Narla RK
– volume: 9
  start-page: 2316
  year: 2003
  ident: e_1_2_1_45_2
  article-title: Response to epidermal growth factor receptor inhibitors in non‐small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal‐regulated kinase or Akt kinase pathways
  publication-title: Clin Cancer Res
  contributor:
    fullname: Janmaat ML
– volume: 4
  start-page: 1778
  year: 2005
  ident: e_1_2_1_48_2
  article-title: Oral treatment of the TRAMP mice with doxazosin suppresses prostate tumor growth and metastasis
  publication-title: Prostate
  contributor:
    fullname: Chiang CF
– volume: 137
  start-page: 43
  year: 1998
  ident: e_1_2_1_3_2
  article-title: Synthesis of some new biologically active 2,3‐disubstituted quinazolin‐4‐ones
  publication-title: Boll Chim Farm
  contributor:
    fullname: Abdel‐Rahman TM
– volume: 28
  start-page: 745
  year: 1989
  ident: e_1_2_1_9_2
  article-title: 2,3‐Disubstituted quinazolinones and their antiparkinsonian activity
  publication-title: Ind J Chem Sect B, Org Chem Incl Med Chem
  contributor:
    fullname: Naithani PK
– ident: e_1_2_1_44_2
  doi: 10.1046/j.1440-1827.2001.01204.x
– volume: 13
  start-page: 335
  year: 1998
  ident: e_1_2_1_20_2
  article-title: EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5
  publication-title: Int J Oncol
  contributor:
    fullname: Modjtahedi H
– volume: 3
  start-page: 1769
  year: 2004
  ident: e_1_2_1_41_2
  article-title: Selective induction of G2/M arrest and apoptosis in HL‐60 by a potent anticancer agent, HMJ‐38
  publication-title: Anticancer Res
  contributor:
    fullname: Yang JS
– ident: e_1_2_1_43_2
  doi: 10.1016/S0016-5085(98)70312-9
– ident: e_1_2_1_35_2
  doi: 10.1097/00001813-200409000-00011
– ident: e_1_2_1_25_2
  doi: 10.1007/BF02931453
– ident: e_1_2_1_21_2
  doi: 10.1007/BF00689203
– volume: 24
  start-page: 1769
  year: 2004
  ident: e_1_2_1_47_2
  article-title: Selective induction of G2/M arrest and apoptosis in HL‐60 by a potent anticancer agent, HMJ‐38
  publication-title: Anticancer Res
  contributor:
    fullname: Yang JS
– ident: e_1_2_1_4_2
  doi: 10.1002/ardp.19903231004
– ident: e_1_2_1_17_2
  doi: 10.1021/jm00089a021
– ident: e_1_2_1_13_2
  doi: 10.1007/s002800050608
– ident: e_1_2_1_31_2
  doi: 10.1016/S1368-8375(98)00118-3
– ident: e_1_2_1_36_2
  doi: 10.1158/0008-5472.CAN-04-1905
– volume: 1
  start-page: 52
  year: 2001
  ident: e_1_2_1_12_2
  article-title: Biological activity of some 4‐anilinoquinazolines: cytotoxic, genotoxic and antiprotease effects, induction of necrosis and changes of actin cytoskeleton
  publication-title: Neoplasma
  contributor:
    fullname: Jantovnnná S
– ident: e_1_2_1_40_2
  doi: 10.1097/01.ju.0000138524.18870.af
– ident: e_1_2_1_8_2
  doi: 10.1093/jnci/82.9.749
– ident: e_1_2_1_15_2
  doi: 10.1110/ps.8.3.467
– ident: e_1_2_1_11_2
  doi: 10.1021/bi981881d
– volume: 6
  start-page: 1174
  year: 2004
  ident: e_1_2_1_38_2
  article-title: The tyrosine kinase inhibitor ZD6474 inhibitors tumour growth in an intracerebral rat glioma model
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6602108
  contributor:
    fullname: Sandstrom M
– ident: e_1_2_1_10_2
  doi: 10.1016/S0014-827X(98)00002-0
– ident: e_1_2_1_22_2
  doi: 10.1038/bjc.1998.747
– ident: e_1_2_1_46_2
  doi: 10.1124/jpet.102.039651
– start-page: 304
  volume-title: Advances in Heterocyclic Chemistry
  year: 1963
  ident: e_1_2_1_2_2
  contributor:
    fullname: Wiseloge FW
SSID ssj0009630
Score 1.8570641
Snippet Quinazolines are multitarget agents, which have broad spectrum of biological activity, and some of them are now in cancer clinical testing....
Abstract Quinazolines are multitarget agents, which have broad spectrum of biological activity, and some of them are now in cancer clinical testing....
Quinazolines are multitarget agents, which have broad spectrum of biological activity, and some of them are now in cancer clinical testing. 3-(5-nitro-2-...
SourceID proquest
crossref
pubmed
wiley
istex
SourceType Aggregation Database
Index Database
Publisher
StartPage 519
SubjectTerms Animals
apoptosis
Apoptosis - drug effects
caspase 3
Caspase 3 - metabolism
cell cycle
Cell Cycle - drug effects
cell growth
cell growth, cell cycle
Cell Line, Tumor
Cell Proliferation - drug effects
DNA Fragmentation - drug effects
Dose-Response Relationship, Drug
Enzyme Activation - drug effects
Fibroblasts - drug effects
Fibroblasts - metabolism
L1210 and NIH-3T3 cells
Mice
Molecular Structure
NIH 3T3 Cells
quinazoline derivative
Quinazolines - chemistry
Quinazolines - pharmacology
Time Factors
Triazoles - chemistry
Triazoles - pharmacology
Title The effect of 3-(5-nitro-2-thienyl)-9-chloro-5-morpholin-4-yl[1,2,4]triazolo[4,3-c]quinazoline on cell growth, cell cycle, induction of DNA fragmentation, and activity of caspase 3 in murine leukemia L1210 cells and fibroblast NIH-3T3 cells
URI https://api.istex.fr/ark:/67375/WNG-G12NRBMX-V/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcbf.1296
https://www.ncbi.nlm.nih.gov/pubmed/16342136
https://search.proquest.com/docview/20128325
Volume 24
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFDZoiMsLl3ErVyMhBFLSNbbjNo9bR1cQ68O0QaVqimzXXqe2CbSpoHviJ_Ab-SWcEzerhkBCPDh2Ejs-jo_tz5dzDiEvVUsDDGXNUHMXh8LEzRBAvQy1Ui6yxgGkQAHn_Z7sHon3_bi_OlWJsjBeP8T5ghu2jLK_xgau9HxrrTTUaFeHwQq1bUe8iae5dg_WmqOAr1bLKzyUoiUqvbMNtlUlvDASXcGf-u1PMPMiai2Hnc4tMqgI9qdNxvVFoevm7Dddjv9Xotvk5gqN0m3PPnfIZZttkqvePuVyk1xvV-bg7l66BgxF_ekPmjvKf37_8TqGC3QJsxx8Bq4YQUexnLyBYALOjCZ5-Q7jTXOoUbQQBGEBbjkZRAELxDHaDTmDDAciwI-a4y-L0wyfQHlonlHcWqAns_xrMQr8jVkCsQE9zYZe9S3Ss9vbpm6mTqYrWaosoCobUhTbQOsYGMUo6D3nlnJISae4y2DpxC7GUERFP6CKs_Lz8zKhgz-Za5haFLT3rgt08UPuX98jR523h-1uuDIjERreQrZzcRJb03IJeEPBGhCOYEw2uMPYsAA4h7opLJMO5oJSKKMYty7S0iVOA57i98lGlmf2IaGNGGarjuuhTBTgUJOYyBjDmJYykTZRNfKiYqn0s9cWknq90CyF2k2xdmvkVclr5xHUbIyn65px-qm3l-5FrHews99PP9bI84oZU6hrLKLKbL6YpwxRBWdxjTzwPLrOTHLBIo6ZlJz2VyrS9k4H_Uf_GvExuVGuPpVimE_IRjFb2KeAxwr9rGx5vwBa9zxE
link.rule.ids 315,783,787,1378,27937,27938,46307,46731
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFDZjE4wXLuNWbjMSQiAlXWMnbiOeto6ugzYPUweVxhTZrr1NbRNoU0H3xE_gN_JLOCdpVg2BhHhw7CR2fByfY3--nUPIC9lQAENZ3VXcBq6vg7oLoF64SkrrGW0BUuAB524k2of-u37QXyFvyrMwhX6Iiwk3lIy8vUYBxwnpraXWUK1sFXorcZWsgbRzlMrdg6XuKOCsxQQLd4Xf8EvNszW2Vaa81Bet4W_99iegeRm35h1P6xb5VJJc7DcZVmeZqurz37Q5_meZbpObC0BKtwsOukNWTLJBrhUmKucbZL1ZWoS7e-U68BQtNoDQ1FL-8_uPVwFcoFWYpOAzcNkptBXz0WsIhuD06SjN32G8cQqVikaCIOyDm4-OPIc5_jGaDjmHDI98Bz-qj7_MzhJ8AgWiaUJxdYGeTNKv2alT3Og5EOvQs2RQaL9FenajbWon8mS8OE6VOFQmA4onN9BABkbREhrQqaEcUtIxLjQYOjKzIRRR0g5qOcs_P80TWviVqYLRRUaj_TbQxXu8eH2PHLbe9pptd2FJwtW8gZxngzAwumFD8AY-q0HYg25Z4yJjzQDmHKi6b5iwMBwUvtSScWM9JWxoFUAqfp-sJmliHhJaC2DAarkaiFACFNWh9rTWjCkhQmFCWSHPS56KPxcKQ-JCNTSLoXZjrN0KeZkz20UEORniBrt6EH-M9uI9j0UHO91-_KFCNktujKGusYgyMelsGjMEFpwFFfKgYNJlZoL7zOOYSc5qf6Uibu600H_0rxE3yXq71-3Enf3o_WNyI5-Myk9lPiGr2WRmngI8y9SzXAx_Acn-QF0
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFDawicELl3ErtxkJoSElXWMnbvO4dXQbbBGaNqhUTZHt2OvUNhltKuie-An8Rn4J5yTNqiGQEA-OncSOj-Nj-_PlnEPIa9lSAENZ01XcBq6vg6YLoF64SkrrGW0BUqCA80Ekdo_9992gOz9VibIwpX6IywU3bBlFf40N_DyxGwuloVrZOgxW4gZZ9gVwKgKiw4XqKGCs-foKd4Xf8ivFsw22UaW8MhQt41_99ieceRW2FuNO5y7pVRSXx00G9Wmu6vriN2WO_1eke-TOHI7SzZJ_7pPrJl0lN0sDlbNVcqtd2YN7cG0FOIqWxz9oZin_-f3HegAX6BPGGfgMXN6HnmI2fAvBEJzuD7PiHcYbZVClaCIIwj642bDnOczxT9BwyAVk2PMd_Kg--TI9S_EJlIdmKcW9BXo6zr7mfae80TMg1qFnaVLqvkV6tqNNasfydDQXpkodKtOEotwGmsfAKFpC9zkxlENKOsJtBkOHZjqAIkq6jzrOis9PioQW_mSmYG6R02hvF-jiR7x8_ZAcd94dtXfduR0JV_MW8p0NwsDolg3BS3zWgLAHg7LGLcaGAcSZqKZvmLAwGRS-1JJxYz0lbGgVACr-iCylWWqeENoIYLpquUpEKAGI6lB7WmvGlBChMKGskVcVS8XnpbqQuFQMzWKo3Rhrt0beFLx2GUGOB3i8rhnEn6OdeMdj0eHWQTf-VCNrFTPGUNdYRJmabDqJGcIKzoIaeVzy6CIzwX3mccyk4LS_UhG3tzroP_3XiGtk5eN2J97fiz48I7eLlahCJPM5WcrHU_MCsFmuXhaN8Bf4Cj8M
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+effect+of+3%E2%80%90%285%E2%80%90nitro%E2%80%902%E2%80%90thienyl%29%E2%80%909%E2%80%90chloro%E2%80%905%E2%80%90morpholin%E2%80%904%E2%80%90yl%5B1%2C2%2C4%5Dtriazolo%5B4%2C3%E2%80%90c%5Dquinazoline+on+cell+growth%2C+cell+cycle%2C+induction+of+DNA+fragmentation%2C+and+activity+of+caspase+3+in+murine+leukemia+L1210+cells+and+fibroblast+NIH%E2%80%903T3+cells&rft.jtitle=Cell+biochemistry+and+function&rft.au=Jantov%C3%A1%2C+S.&rft.au=Leta%C5%A1iov%C3%A1%2C+S.&rft.au=Repick%C3%BD%2C+A.&rft.au=Ov%C3%A1dekov%C3%A1%2C+R.&rft.date=2006-11-01&rft.pub=John+Wiley+%26+Sons%2C+Ltd&rft.issn=0263-6484&rft.eissn=1099-0844&rft.volume=24&rft.issue=6&rft.spage=519&rft.epage=530&rft_id=info:doi/10.1002%2Fcbf.1296&rft.externalDBID=10.1002%252Fcbf.1296&rft.externalDocID=CBF1296
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0263-6484&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0263-6484&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0263-6484&client=summon